Harmonization of antimicrobial breakpoints in Europe — Can it be achieved?

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Microbiology Newsletter

• Publication date

  2004-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0196-4399(04)80015-1
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of new susceptibility breakpoints on reporting of resistance in Streptococcus pneumoniae--United States, 2003.

  2004cited by this paper
• European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria.

  2003cited by this paper
• Impact of pharmacodynamics on breakpoint selection for susceptibility testing.

  2003cited by this paper
• A new method for normalized interpretation of antimicrobial resistance from disk test results for comparative purposes.

  2003cited by this paper
• Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors.

  2003cited by this paper
• Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts

  2003cited by this paper
• Antimicrobial susceptibility testing of Mycobacterium tuberculosis

  2002cited by this paper
• Emerging infections--a coordinated European approach.

  2001cited by this paper
• Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests.

  2001cited by this paper
• Interpretatie van gevoeligheidsonderzoek en gevoeligheidscriteria voor antibacteriële middelen in Nederland.

  2000cited by this paper
• Susceptibility testing of bacteria and fungi. Report from "the Norwegian Working Group on Antibiotics".

  1997cited by this paper
• Antimicrobial susceptibility testing in Sweden. II. Species-related zone diameter breakpoints to avoid interpretive errors and guard against unrecognized evolution of resistance.

  1997cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper

• Exploring the Biomedical and Photocatalytic Potential of Copper Oxide Modified PdCo2S3-Mo3S6 nanostructures

  2026cites this paper
• Synthesis of Zr–Fe2O3/In2O3 photocatalyst by novel hydrothermal method for highly selective photo inhibition of pathogens, pollutant degradation and DPPH stabilization

  2023cites this paper
• Synthesis of Adenosine 5-monophosphate monohydrate functionalized mesoporous Ag/CuO/MCM-41 nanostructures for enormous mineralization of insistent organic contaminants and photoinhibition of bacteria

  2023cites this paper
• Effect of light-dark conditions on inhibition of Gram positive and gram negative bacteria and dye decomposition in the presence of photocatalyst Co/ZnO nanocomposite synthesized by ammonia evaporation method.

  2022cites this paper
• Surfactant assisted CuO/MCM-41 nanocomposite: Ultra efficient photocatalyst for degradation of methylene blue dye and inactivation of highly drug resistant bacteria

  2021cites this paper
• Rational prioritization strategy allows the design of macrolide derivatives that overcome antibiotic resistance

  2021cites this paper
• Prudent Use of Tylosin for Treatment of Mycoplasma gallisepticum Based on Its Clinical Breakpoint and Lung Microbiota Shift

  2021cites this paper
• Biomedical response under visible-light irradiation promoted by new hydrothermally synthesized SiO2-Zn@Fe2O3 nanofibers.

  2021cites this paper
• Development of a new simple spectroscopic determination coupled acid-motivated delivery system based on fluorescence turn-off MSNs@MPA-ZnS QDs for infection

  2021cites this paper
• Safety demonstration of a microbial species for use in the food chain: Weissella confusa.

  2020cites this paper
• Photo-assisted inactivation of highly drug resistant bacteria and DPPH scavenging activities of zinc oxide graphted Pd-MCM-41 synthesized by new hydrothermal method.

  2020cites this paper
• Antimicrobial Susceptibility Testing of Bacteria of Veterinary Origin

  2019cites this paper
• Antimicrobial Susceptibility Testing of Bacteria of Veterinary Origin

  2018cites this paper
• Etest Cannot Be Recommended for In Vitro Susceptibility Testing of Mucorales

  2015cites this paper
• A Statistical Approach for Determination of Disk Diffusion-Based Cutoff Values for Systematic Characterization of Wild-Type and Non-Wild-Type Bacterial Populations in Antimicrobial Susceptibility Testing

  2015cites this paper
• Introduction of the VITEK 2 Compact and Implementation of EUCAST Guidelines in a Microbiology Department

  2015influential citation
• Validation of EUCAST zone diameter breakpoints against reference broth microdilution.

  2014cites this paper
• The Evolving Role of Antifungal Susceptibility Testing

  2013cites this paper
• Emergence of resistance to antibacterial agents: the role of quaternary ammonium compounds--a critical review.

  2012cites this paper
• Susceptibility of coagulase-negative staphylococci to a kanamycin and cefalexin combination.

  2012cites this paper
• Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.

  2011cites this paper
• Setting interpretive breakpoints for antimicrobial susceptibility testing using disk diffusion.

  2011cites this paper
• Antimicrobial Susceptibility to Azithromycin among Salmonella enterica Isolates from the United States

  2011cites this paper
• Comparison of the Broth Microdilution (BMD) Method of the European Committee on Antimicrobial Susceptibility Testing with the 24-Hour CLSI BMD Method for Testing Susceptibility of Candida Species to Fluconazole, Posaconazole, and Voriconazole by Use of Epidemiological Cutoff Values

  2011cites this paper
• Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

  2011cites this paper
• Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.

  2011cites this paper
• linical breakpoints for the echinocandins and Candida revisited : Integration of olecular , clinical , and microbiological data to arrive at species-specific nterpretive criteria

  2011cites this paper
• Definitions and Epidemiology of Candida Species not Susceptible to Echinocandins

  2011cites this paper
• Validation of 24-Hour Posaconazole and Voriconazole MIC Readings versus the CLSI 48-Hour Broth Microdilution Reference Method: Application of Epidemiological Cutoff Values to Results from a Global Candida Antifungal Surveillance Program

  2011cites this paper
• Wild-Type MIC Distributions and Epidemiologic Cutoff Values for Fluconazole and Candida: Time for New Clinical Breakpoints?

  2010cites this paper
• Wild-Type MIC Distributions and Epidemiological Cutoff Values for Posaconazole and Voriconazole and Candida spp. as Determined by 24-Hour CLSI Broth Microdilution

  2010cites this paper
• Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Candida Species to Anidulafungin, Caspofungin, and Micafungin

  2010cites this paper
• Supranational surveillance of antimicrobial resistance: The legacy of the last decade and proposals for the future.

  2010cites this paper
• Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.

  2010cites this paper
• Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species

  2010cites this paper
• Prevalence and antimicrobial resistance of Campylobacter jejuni and Campylobacter coli isolated from cattle between 2002 and 2006 in France.

  2010cites this paper
• Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins and Candida spp

  2009cites this paper
• Antimicrobial susceptibility in Escherichia coli of human and avian origin--a comparison of wild-type distributions.

  2009cites this paper
• Developments in the recent past—hospital hygiene and antimicrobials

  2007cites this paper
• Development of Standardized Antimicrobial Susceptibility Testing Methods and Aeromonas salmonicida Epidemiologic Cutoff Values for Antimicrobial Agents Used in Aquaculture

  2007cites this paper
• In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance

  2006cites this paper
• Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation.

  2006cites this paper
• Epidemiologic cutoff values for antimicrobial agents against Aeromonas salmonicida isolates determined by frequency distributions of minimal inhibitory concentration and diameter of zone of inhibition data.

  2006influential citation
• Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.

  2006cites this paper
• European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing.

  2006influential citation
• BSAC standardized disc susceptibility testing method (version 4).

  2005cites this paper
• BSAC standardized disc susceptibility testing method (version 8).

  2004cites this paper
• Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway

  2004cites this paper